Related Experiment Videos

Prenatal screening for open neural tube defects

Jacob A Canick1, Leonard H Kellner, Allan T Bombard

  • 1Division of Prenatal and Special Testing, Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Brown Medical School, 101 Dudley Street, Providence, RI 02905-2401, USA. jcanick@wihri.org

Insights

Prenatal screening for birth defects uses alpha-fetoprotein (AFP) tests. This article reviews AFP

Area of Science:

  • Obstetrics and Gynecology
  • Clinical Chemistry
  • Medical Diagnostics

Background:

  • Prenatal screening for birth defects began in the 1970s.
  • Discovery of elevated alpha-fetoprotein (AFP) in maternal serum and amniotic fluid indicated fetal open neural tube defects.
  • AFP testing is now standard in routine obstetric care.

Purpose of the Study:

  • To discuss the use of alpha-fetoprotein (AFP) in prenatal screening for open neural tube defects.
  • To examine the role of the laboratory in AFP screening.
  • To explore laboratory interactions with practicing obstetricians regarding AFP testing.

Main Methods:

  • Review of the historical development and current application of AFP screening.
  • Discussion of laboratory procedures and quality control for AFP testing.
  • Analysis of communication and collaboration between laboratories and obstetricians.

Main Results:

  • AFP screening has significantly advanced prenatal diagnostics for open neural tube defects.
  • Effective laboratory practices are crucial for accurate AFP test results.
  • Strong communication between labs and clinicians improves patient care and screening efficacy.

Conclusions:

  • Alpha-fetoprotein (AFP) testing remains a vital component of prenatal screening for open neural tube defects.
  • The laboratory plays a critical role in the success of AFP screening programs.
  • Optimizing the interaction between laboratories and obstetricians enhances the overall effectiveness of prenatal care.

Related Concept Videos